NCT06918366View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Inhaled XQ-001 in Healthy Subjects

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

August 1, 2024

Primary Completion Date

March 31, 2025

Study Completion Date

May 30, 2025

Conditions
Healthy
Interventions
DRUG

Part A - single rising dose 1

Inhaled XQ-001

DRUG

Part A - single rising dose 2

Inhaled XQ-001 or Placebo

DRUG

Part A - single rising dose 3

Inhaled XQ-001 or Placebo

DRUG

Part A - single rising dose 4

Inhaled XQ-001 or Placebo

DRUG

Part A - single rising dose 5

Inhaled XQ-001 or Placebo

DRUG

Part A - single rising dose 6

Inhaled XQ-001 or Placebo

DRUG

Part B - mutiple rising dose 1

Inhaled XQ-001 or Placebo

DRUG

Part B - mutiple rising dose 2

Inhaled XQ-001 or Placebo

Trial Locations (1)

610041

West China Hospital, Chendu

Sponsors
All Listed Sponsors
lead

Brilliant Inspiration Biotherapeutics

INDUSTRY

NCT06918366 - A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Inhaled XQ-001 in Healthy Subjects | Biotech Hunter | Biotech Hunter